The development of innovative technologies and the advances in the genetics and genomics, have offered new opportunities for personalized treatment in oncology. Although the selection of the patient based on the molecular characteristics of the neoplasm has the potential to revolutionize the therapeutic scenario of oncology, this approach is extremely challenging. The access, homogeneity, and economic sustainability of the required genomic tests should be warranted in the clinical practice, as well as the specific scientific and clinical expertise for the choice of medical therapies. All these elements make essential the collaboration of different specialists within the Molecular Tumor Boards (MTBs). In this position paper, based on experts' opinion, the AIOM-SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies critically discuss the available molecular profiling technologies, the proposed criteria for the selection of patients candidate for evaluation by the MTB, the criteria for the selection and analysis of biological samples, and the regulatory and pharmaco-economic issues.
Antonio Russo, 1., Lorena Incorvaia, 2., Ettore Capoluongo, 3., Pierosandro Tagliaferri, 4., Antonio Galvano, 2., Marzia Del Re, 5., Umberto Malapelle, 6., Rita Chiari, 7., Pierfranco Conte, 8., Romano Danesi, 5., Matteo Fassan, 9., Roberto Ferrara, 1., Genuardi, M., Paola Ghiorzo, 1., Stefania Gori, 1., Fiorella Guadagni, 1., Antonio Marchetti, 1., Paolo Marchetti, 1., Massimo Midiri, 1., Nicola Normanno, 1., Francesco Passiglia, 1., Carmine Pinto, 2., Nicola Silvestris, 2., Giovanni Tallini, 2., Simona Vatrano, 2., Bruno Vincenzi, 2., Saverio Cinieri, 2., Giordano Beretta, 2., The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies, <<CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY>>, 2022; 2022 (169): 1-9. [doi:10.1016/j.critrevonc.2021.103567] [https://hdl.handle.net/10807/219707]
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies
Genuardi, M;
2022
Abstract
The development of innovative technologies and the advances in the genetics and genomics, have offered new opportunities for personalized treatment in oncology. Although the selection of the patient based on the molecular characteristics of the neoplasm has the potential to revolutionize the therapeutic scenario of oncology, this approach is extremely challenging. The access, homogeneity, and economic sustainability of the required genomic tests should be warranted in the clinical practice, as well as the specific scientific and clinical expertise for the choice of medical therapies. All these elements make essential the collaboration of different specialists within the Molecular Tumor Boards (MTBs). In this position paper, based on experts' opinion, the AIOM-SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies critically discuss the available molecular profiling technologies, the proposed criteria for the selection of patients candidate for evaluation by the MTB, the criteria for the selection and analysis of biological samples, and the regulatory and pharmaco-economic issues.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
